NetworkNewsBreaks

WednesdayFeb 26, 2020 1:01 pm

NetworkNewsBreaks – Enphase Energy, Inc. (NASDAQ: ENPH) Featured in ROTH Equity Research Report

Enphase Energy, Inc. (NASDAQ: ENPH) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Heading into Q4 results, we had previewed potential for weakness in shares on potential coronavirus issues and channel inventory. It appears we may have misread the situation, and management has a path to likely sidestep the challenges assuming the situation in China remains stable and improves. All in, ENPH delivered an impressive Q4 and strong Q1 guide, and we continue to see upside to shares. Reiterate Buy and 2020 Top Pick, PT to $55 from $30.” To request…

Continue Reading

WednesdayFeb 26, 2020 12:52 pm

NetworkNewsBreaks – Shopify Inc. (NYSE: SHOP) Featured in ROTH Equity Research Report

Shopify Inc. (NYSE: SHOP) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Incremental Merchant solution strength (Shopify Pay and other tools adoption) resulted in 4Q outperformance and a ~230bps re-acceleration in topline growth. Growth rates overall (revenue/metrics) continue to trend lower with additional slowdowns implied in the modestly better FY20 revenue guidance (~1,000bps slowdown at the top end), with incremental growth investments suppressing profits. While we believe SHOP has numerous growth drivers at its disposal, high cost and longer lead times likely don’t drive sustainable growth acceleration (despite healthy fundamentals). Maintain…

Continue Reading

WednesdayFeb 26, 2020 12:43 pm

NetworkNewsBreaks – Applied Genetic Technologies Corporation (NASDAQ: AGTC) Featured in ROTH Equity Research Report

Applied Genetic Technologies Corporation (NASDAQ: AGTC) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, AGTC announced that the final two dose-cohorts of its Phase 1/2 XLRP study are now fully-enrolled. AGTC enrolled a total of nine patients into the higher and highest dose-cohorts, and plans to present interim data in 2H20, along with 12-month data from Groups 1-4. The updated data should provide insights on the appropriate time-point for analysis, as well as the influence of higher doses on endpoints of interest ahead of the initiation of a pivotal…

Continue Reading

WednesdayFeb 26, 2020 12:34 pm

NetworkNewsBreaks – Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) Featured in ROTH Equity Research Report

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, ALNA announced proposed changes to URIROX-2, including reduction of overall EH patients (200 vs. 400) and adding an interim analysis of 130 patients at six months treated expected 3Q21, with full readout for BLA filing in 1Q22. As discussed in our report below, we believe strong stat. sig. UOx reductions from URIROX-1 and KS rates reduce risk from decreasing the number patients studied. Importantly, we see streamlining as limiting any financial overhang (~1/3 the cost of…

Continue Reading

WednesdayFeb 26, 2020 12:22 pm

NetworkNewsBreaks – Evolus, Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

Evolus, Inc. (NASDAQ: EOLS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Evolus reported full 4Q19 results today that were solid but largely expected following the company's pre-announcement on Jan 9. We maintain our BUY rating on EOLS shares as we expect the company to continue to execute on the commercialization of Jeuveau in a highly attractive facial toxin market. However, we appreciate that investors remain concerned about the ongoing legal issues between their partner Daewoong and competitor Medytox over Jeuveau’s development and that will remain an overhang for the stock,…

Continue Reading

WednesdayFeb 26, 2020 12:21 pm

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all…

Continue Reading

WednesdayFeb 26, 2020 11:43 am

NetworkNewsBreaks – Xencor, Inc. (NASDAQ: XNCR) Featured in Mizuho Securities Research Report

Xencor, Inc. (NASDAQ: XNCR) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “XNCR's 4Q19 EPS update was largely in line with our thesis as we see 2020 as a year of gaining visibility on the critical paths for wholly-owned T-cell engagers (TCEs), most notably plamotamab for B cell malignancies, which showed potential for advancement at ASH this past year. We see the next steps for plamotamab as locking down dose and schedule in 2020, and we expect incremental news from other pipeline candidates, which we see as valuation expansion opportunities. 4Q19…

Continue Reading

WednesdayFeb 26, 2020 11:15 am

NetworkNewsBreaks – Revance Therapeutics, Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research Report

Revance Therapeutics, Inc. (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Revance reported earnings yesterday. 4Q19 EPS of $(0.99) was slightly below FactSet consensus of $(0.95) which we believe it is immaterial for a developmental stage Biotech company. The PDUFA date for DAXI in glabellar lines is 11/25/2020, and important data catalysts are expected throughout 2020. We continue to see RVNC shares as attractive today given the overall growth opportunities in neuromodulators and facial fillers, as well as further upside from the company's therapeutics pipeline.” To request access to…

Continue Reading

WednesdayFeb 26, 2020 11:04 am

NetworkNewsBreaks – Why National Storm Recovery Inc. (NSRI) Is ‘One to Watch’

National Storm Recovery (OTC: NSRI) is working to find a solution for the treatment and handling of tree debris that is traditionally sent to local landfills and disposal sites, creating an environmental burden and stress on disposal sites throughout the United States. An article discussing the company reads, “National Storm plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. . . . The company has received final…

Continue Reading

WednesdayFeb 26, 2020 11:00 am

NetworkNewsBreaks – Sharing Services Global Corporation (SHRG) Provides Comprehensive Support to Independent Sales Force

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company, provides individuals who join the company’s ranks an opportunity to enter the booming direct selling-industry with comprehensive support and a compelling line of products to help them reach success. In 2018, the number of people involved in direct selling in the United States alone surpassed 42 million (http://nnw.fm/a2sZI). An article discussing the company reads, “Those who join the growing ranks of SHRG Elepreneurs are overall an inspiring group. Based on the DSA’s most recent available data, direct sellers are more affluent than the average American, with 58% of direct sellers reporting…

Continue Reading